ArticleAnnals of thoracic surgery short reports2026
Segmentectomy vs Lobectomy for Peripheral Early-Stage Non-Small Cell Lung Cancer in Patients With Radiologically High Risk Tumors.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing use of segmentectomy for early-stage peripheral non-small cell lung cancer (NSCLC) raises questions about its oncologic adequacy compared with lobectomy, particularly for tumors with high-risk features. This study aimed to compare oncologic outcomes between segmentectomy and lobectomy for clinical stage IA1-2 peripheral NSCLC, stratified by radiologic tumor risk. Methods: This retrospective single-center study analyzed 527 patients with peripheral NSCLC ≤2 cm who underwent either lobectomy (n = 240), or segmentectomy (n = 287) from January 2017 to December 2024. High-risk tumors were defined as cT1b, solid dominant, and hypermetabolic (maximal standardized uptake value >2.5). Primary end points included 4-year overall survival (OS) and event-free survival (EFS). Cox regression analysis was performed to identify independent predictors of EFS. Results: High-risk tumors comprised 122 lobectomies (51%) and 73 segmentectomies (25%). For low-risk tumors, there was no significant difference in 4-year OS or EFS (OS: lobectomy 85% vs segmentectomy 84% [ Conclusions: Segmentectomy demonstrates oncologically equivalent outcomes compared with lobectomy for both low-risk and high-risk clinical stage IA1-2 peripheral NSCLC. These findings support the oncologic safety of segmentectomy as an alternative to lobectomy in appropriately selected patients with small peripheral NSCLC, even in the high-risk tumor subset.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.